Yanan Zhu
Stock Analyst at Wells Fargo
(1.81)
# 3,036
Out of 4,873 analysts
65
Total ratings
27.45%
Success rate
-4.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $100 → $75 | $17.46 | +329.55% | 3 | Jun 17, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $1.56 | +925.64% | 3 | May 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $50 → $45 | $13.95 | +222.58% | 7 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $1 | $0.25 | +295.26% | 3 | May 14, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $16.76 | +317.66% | 3 | May 7, 2025 | |
| RGLS Regulus Therapeutics | Downgrades: Equal-Weight | $9 | $8.01 | +12.36% | 2 | May 1, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $2.32 | +158.62% | 3 | Mar 21, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $2.94 | +240.14% | 2 | Mar 12, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.16 | +244.83% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $14.33 | +109.35% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $9.56 | +423.01% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $2.19 | +82.65% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $32 | $9.56 | +234.73% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $40.00 | +92.50% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $15.72 | +154.45% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $47.66 | +36.38% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.26 | +820.25% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $1.78 | +1,304.49% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $29.90 | +67.22% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.58 | +587.29% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $4.51 | +9,877.83% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.44 | +309.84% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $560.53 | -41.84% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $17.46
Upside: +329.55%
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $1.56
Upside: +925.64%
Arcturus Therapeutics Holdings
May 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $13.95
Upside: +222.58%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.25
Upside: +295.26%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $16.76
Upside: +317.66%
Regulus Therapeutics
May 1, 2025
Downgrades: Equal-Weight
Price Target: $9
Current: $8.01
Upside: +12.36%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $2.32
Upside: +158.62%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $2.94
Upside: +240.14%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.16
Upside: +244.83%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $14.33
Upside: +109.35%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $9.56
Upside: +423.01%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $2.19
Upside: +82.65%
Nov 12, 2024
Maintains: Overweight
Price Target: $136 → $32
Current: $9.56
Upside: +234.73%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $40.00
Upside: +92.50%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $15.72
Upside: +154.45%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $47.66
Upside: +36.38%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.26
Upside: +820.25%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $1.78
Upside: +1,304.49%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $29.90
Upside: +67.22%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.58
Upside: +587.29%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $4.51
Upside: +9,877.83%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.44
Upside: +309.84%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $560.53
Upside: -41.84%